Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH.

Jérôme BoursierR AntyL VonghiaV MoalT VanwolleghemC M CanivetS MichalakS BonnafousP MichielsenF ObertiA IannelliL Van GaalS PatourauxO BlanchetA VerrijkenP GualM-C RousseletA DriessenG HunaultS BertraisA TranPaul CalèsS Francque

Published in: Alimentary pharmacology & therapeutics (2018)

The new blood test MACK-3 accurately diagnoses fibrotic NASH. This new test will facilitate patient screening and inclusion in NAFLD therapeutic trials and will enable the identification of patients who will benefit from the treatments once approved.

Keyphrases

clinical practice
systemic sclerosis
idiopathic pulmonary fibrosis
case report
combination therapy
drug administration